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Background: One of the unique features of gammaretroviruses is that they contain an additional extended form of
Gag, glyco-gag, which initiates in the leader sequence. MuLV glyco-gag, gPr80Gag, promotes retrovirus replication
and disease progression. Although virtually all infectious MuLVs encode glyco-gag, XMRV (xenotropic murine
leukemia virus-related virus) lacks the classical gPr80Gag sequence. We examined XMRV to determine if its leader
sequence contains glyco-gag activity, whether the presence of conventional gPr80Gag affects replication of XMRV,
and we describe the evolution of glyco-gag-deficient MuLVs in Mus.
Results: We introduced several mutations disrupting two putative but noncanonical glyco-gag proteins in the
leader sequence region in XMRV and found that those mutations did not affect virus release nor susceptibility to
the antiviral activity of hA3G (human APOBEC3G). A chimeric XMRV encoding the Moloney MuLV (M-MuLV) leader
sequence (MXMRV) demonstrated that M-MuLV glyco-gag facilitated MXMRV release and increased infectivity.
Infectivity assays with several cell lines showed that glyco-gag increases XMRV infectivity in all cell lines tested, but
the level of this increase varies in different cell lines. Because MuLV glyco-gag counteracts mouse APOBEC3, we
investigated whether M-MuLV glyco-gag enhances XMRV infection by counteracting human APOBEC3. Comparison
of hAPOBEC3 isoforms expressed in different cell lines indicated that hA3B was the most likely candidate for a
restrictive hA3. However over-expression of hA3B showed no enhanced restriction of infection by XMRV compared
to MXMRV. Endogenous MuLVs in the sequenced mouse genome were screened for canonical glyco-gag, which
was identified in two clades of xenotropic MuLVs (X-MuLVs) and ecotropic MuLVs, but not in other X-MuLVs or in
any polytropic MuLVs.
Conclusions: M-MuLV glyco-gag facilitates XMRV replication, and the leader sequence region in XMRV does not
encode proteins equivalent to M-MuLV glyco-gag. The fact that the ability of glyco-gag to enhance XMRV infection
varies in different cell lines suggests a glyco-gag sensitive restrictive factor that further reduces XMRV infectivity. The
M-MuLV glyco-gag enhancement for XMRV replication is through a hAPOBEC3 independent mechanism. The
absence of glyco-gag in MuLVs carried by western European mice suggests that loss of this sequence is a relatively
recent event with limited subspecies distribution.
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Gammaretroviruses infect a variety of host species and
are causative agents of various diseases including malig-
nant tumors, neurological disorders and immunodefi-
ciency [1-4]. One of the unique features of
gammaretroviruses is that many encode an additional
form of Gag protein, glycosylated Gag (glyco-gag). In
Moloney murine leukemia virus (M-MuLV) glyco-gag
(gPr80gag) is translated from unspliced viral mRNA via
an upstream CUG initiation codon in frame with the
AUG initiation codon for the Pr65gag polyprotein precur-
sor for the viral core proteins [5-7]. gPr80gag contains 88
additional amino-terminal (N-terminal) amino acids, in-
cluding a signal peptide that leads to transport of the
protein into the rough endoplasmic reticulum, where it
is glycosylated and exported to the cell surface [8]. At
the cell surface, mature gPr80gag is cleaved into two pro-
teins of 55 (N-terminal) and 40 (C-terminal) kDa. The
55 kDa portion is maintained in a type II integral mem-
brane configuration, with the unique 88 amino acids in
the cytosol [5,8,9]. In mice, gPr80gag is a major patho-
genic determinant for neuropathic FrCasE MuLV [10-
12]. MuLVs mutant in gPr80gag show replication defects
in mice, and there is a strong selection for recovery of
glyco-gag function [13-15]. Recently we found that
glyco-gag facilitates viral assembly or release through an
interferon-sensitive pathway, and in particular through
lipid rafts [15-17]. Other investigators have recently
reported that gPr80gag can complement a replication de-
fect for Nef-negative HIV-1 [18], and that gPr80gag
antagonizes restriction of MuLV by mouse APOBEC3
(mA3, apolopprotein B mRNA-editing enzyme catalytic
polypeptide 3) both in vitro and in vivo [19].
Recently a novel infectious gammaretrovirus related to
MuLVs has been discovered that can infect human cells
[20,21]. This virus, xenotropic murine leukemia virus-
related virus (XMRV), shares 94% overall sequence simi-
larity with xenotropic and polytropic endogenous MuLV
proviruses in the mouse genome. Xenotropic MuLVs
cannot infect laboratory mouse strains because of lack of
a functional receptor, but they can infect cells of wild
mouse species and other species including humans
[22,23]. XMRV infection was initially associated with
human prostate cancer and chronic fatigue syndrome,
but these associations have generally been refuted [24-
26]. Very recently it has been shown that XMRV arose
by recombination between two specific endogenous
MuLV proviruses (preXMRV-1 and preXMRV-2) during
in vivo passage of a human prostate cancer xenograft in
nude mice [26]. Nevertheless, because it is infectious,
XMRV provides a useful tool to study the biology of en-
dogenous xenotropic MuLVs which were presumably in-
fectious in progenitors of modern laboratory mice when
they endogenized [23].Although XMRV is no longer suspected to be a human
pathogen, it is an infectious virus with sequence and
phenotypic differences relative to mouse-derived MuLVs.
Similar to M-MuLV and other exogenous gammaretro-
viruses, XMRV has a leader sequence in the 5’ end of the
viral RNA genome upstream of the AUG for Pr65gag.
However, unlike virtually all infectious MuLVs, XMRV
has no contiguous open reading frame upstream of the
Pr65gag AUG, so it cannot encode a classical gPr80gag-
like glyco-gag [20,27]. On the other hand, this region
does contain two CUG codons followed by in frame cod-
ing sequences that could potentially encode small pro-
teins that might have glyco-gag function. In this report
we tested this possibility and found no evidence for
glyco-gag activity in the leader sequence region of
XMRV. We also generated a chimeric virus expressing
M-MuLV glyco-gag in frame with XMRV Gag, MXMRV.
Studies with MXMRV revealed a restriction factor for
XMRV in some but not all human cell lines tested that
could be counteracted by M-MuLV glyco-gag, but was
independent of human APOBEC3 expression. We also
determined that, while virtually all infectious MuLVs
have an apparently functional glyco-gag sequence,
XMRV and some subsets of endogenous MuLVs lack
glyco-gag, suggesting that the infectious MuLV progeni-
tors of these proviruses were glyco-gag free.Results
XMRV does not encode glyco-gag activity
Urisman et al.. [20] reported that XMRV has a CUG
codon in the 5’ leader sequence 270 bp upstream from
the Pr65gag AUG initiation codon, analogous to exogen-
ous MuLVs such as Moloney and Friend MuLVs (M-
MuLV and F-MuLV). However the leader sequences of
XMRV differ relative to M- and F-MuLV, and some en-
dogenous X-MuLVs (see below). XMRV has a 24 bp de-
letion in the leader sequence, as well as an additional
1 bp deletion, so this CUG would encode a 53 amino
acid protein (p53) from a different reading frame than
Pr65gag (Figure 1). Inspection of the XMRV leader se-
quence also identified a second CUG in a different read-
ing frame followed by an ORF that could potentially
encode a protein of 58 amino acids (p58). Neither of
these putative proteins contain the transmembrane do-
main of the standard glyco-gag sequence. Because glyco-
gag in M- and F-MuLV is associated with efficient viral
replication [15-19], and the N-terminus contains essen-
tial sequences for this activity [17,18], we tested if the
putative small proteins in the XMRV leader sequence
might have biological functions equivalent to glyco-gag.
We introduced mutations that would disrupt expression
of p53, p58 (or both) in a plasmid containing the full-
length XMRV molecular clone, pVP62 (Table 1).
Figure 1 Potential glyco-gag proteins in XMRV. The sequences from the 5’ end of the XMRV genome are shown, with potential open reading
frames. The ATG initiation codon for the Gag polyprotein (poly-Gag) is at nt 608. Two potential CTG initiation codons at nt 340 and 369 followed
by open reading frames to give the potential proteins p53 and p58 are shown.
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MuLV particle release from infected NIH3T3 cells by
directing release through lipid rafts [16]. Compared to
glyco-gag mutant virus, wild-type viral particles had
higher cholesterol content, reduced buoyant density, and
higher sensitivity to the cholesterol depleting agentTable 1 The mutations disrupting expression of putative
glyco-gag proteins in XMRV
Constructs mutation XMRV p53 XMRV p58
pVP62 (WT) None + +
pVP62Δgg0 _ to A (nt 372) - -
pVP62Δgg1 C to AT (nt 382) - -
pVP62Δgg2 T to C (nt 370) + -
pVP62Δgg3 T to C (nt 341) - +
pVP62Δgg4 T to G (nt 354) - +
The mutations to disrupt expression of putative glyco-gag proteins, p53 and
p58, in the leader sequence region of XMRV VP62 are shown. Reference for
original sequence is EF185282.methyl-beta-cyclodextrin (MβCD) for release [16]. The
wild-type pVP62 and the mutants (pVP62Δgg0-4) were
transiently transfected into human 293 T cells, and the
amounts of intracellular Pr65gag protein as well as
released virus were assessed by SDS-PAGE and western
blotting for M-MuLV capsid (CA, p30CA) as described
previously [16]. All of the mutant constructs gave similar
levels of intracellular Gag protein and released virus. In
addition, treatment with MβCD of 293 T cells trans-
fected with pVP62 or the mutant plasmids showed inhib-
ition of virus release, but the MβCD sensitivities were
similar for all plasmids (not shown). Thus, there was no
evidence that the putative p53 and p58 reading frames
upstream of Pr65gag were important for XMRV release.
gPr80gag can complement a replication defect for Nef-
deficient HIV-1 in human lymphocyte cell lines [18], and
it can counteract mouse APOBEC3 (mA3) restriction of
MuLV replication in mouse cells [19]. We therefore
tested the five mutant XMRVs (obtained by transient
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(Figure 2). The mutant VP62Δgg1 showed a major re-
duction in infectivity (80%) and 2 mutants (VP62Δgg0
and VP62Δgg2) showed minor reductions (20-40%).
Quantitative RT-PCR revealed that these mutants also
showed reductions in viral RNA in virions; for these
mutants, the reductions in infectivity could have
reflected reduced RNA packaging. However the mutants
VP62Δgg2 and VP62Δgg4, defective in the putative p58
and p53 respectively, showed no reduction in infectivity
or RNA content. Thus neither p58 nor p53 is required
for viral infectivity.
We also generated wild-type and mutant XMRVs con-
taining human APOBEC3G (hA3G) that has been shown
to restrict XMRV infection [28-31]. 293 T cells were co-
transfected with the XMRV expression plasmids along
with an expression plasmid for epitope-tagged hA3G.
hA3G was incorporated into the wild-type and mutant
XMRV virions with equal efficiencies (not shown).
XMRV containing hA3G showed an 80% reduction in in-
fectivity in HeLa cells, consistent with previous reports
[28,31] (Table 2). The mutant XMRVs showed equivalent
reductions in infectivity, indicating that the putative p53
and p58 proteins did not counteract the inhibitory effects
of hA3G.
M-MuLV glyco-gag facilitates XMRV release through lipid
rafts
Since XMRV does not appear to encode a functional
glyco-gag, we tested if M-MuLV glyco-gag could enhance
virus release through lipid rafts. 293 T cells were co-
transfected with pVP62 along with expression constructs
for different forms of M-MuLV glyco-gag, including full-
length protein (p8065-2) and the essential amino-
terminal 88 amino acids (pHA-gg88), as well as epitope-
tagged proteins (Figure 3 and Additional file 1: FigureFigure 2 Infectivity of XMRV mutants. The wild-type and putative glyco-
expression vectors in 293 T cells) were used to measure infectivity on HeLa
virions was determined by quantitative RT-PCR. Both infectivity and the am
and the relative infectivities and the amounts of viral RNA relative to wild-t
conducted to detect the difference between mean scores in the two group
(*, p< 0.05, **, p< 0.005, ***, p< 0.0005).S1). The different glyco-gag expression constructs
enhanced XMRV release, although to an intermediate
level (ca. 50% increase) compared to enhancement of M-
MuLV release (2-4-fold, [16,17]).
We next tested if a chimeric XMRV virus expressing
glyco-gag would show enhanced release through lipid
rafts. The R, U5 and leader sequences from M-MuLV
were substituted into the equivalent region of XMRV
pVP62, with the M-MuLV glyco-gag sequences in-frame
with XMRV Gag, giving the plasmid pMXMRV
(Figure 4A). We also made two mutants in sequences
surrounding the glyco-gag CUG initiation codon previ-
ously shown to impair expression of glyco-gag [11,18].
pMXMRV and the mutant derivatives were transiently
transfected into 293 T cells, and supernatants from the
cells were used to infect other 293 T cells. As expected,
the cells infected with MXMRV virus showed expression
of glyco-gag (the broad band of 85–95 Kd, Figure 4B).
Cells infected with MXMRV showed enhanced release of
virus as indicated by the amount of Gag proteins. More-
over the MXMRV mutants neither expressed glyco-gag,
nor did they show enhanced virus release. Thus in the
context of infectious virus, M-MuLV glyco-gag could fa-
cilitate release of XMRV, although the enhancement was
again intermediate compared to effects on M-MuLV re-
lease [16]. This was also true for 293 T cells transiently
transfected with pMXMRV vs. pVP62 (Figure 4C and
Additional file 2: Figure S2), and for human DU145 pros-
tate cancer cells productively infected with the two
viruses (Figure 4D).
Cells infected with MXMRV also showed enhanced
(1.5-2-fold) association of Pr65gag with detergent-
resistant membranes (not shown), and MXMRV virions
had a lighter buoyant density than XMRV (Figure 4E).
Both of these properties were consistent with enhanced
release of MXMRV through lipid rafts.gag-mutated XMRV stocks (generated by transient transfection of
cells by a focal immunofluorescence assay. The amount of viral RNA in
ount of viral RNA were normalized based on Capsid protein in viruses,
ype XMRV are shown. Student’s t-test with equal variances was
s and values significantly different from wild-type XMRV are indicated
Table 2 The mutations for putative glyco-gag did not influence anti-viral activity of hA3G in XMRV infection
Virus hA3G Trial 1 Trial 2 Ave± Std
IU/ml* Relative infectivity** IU/ml Relative infectivity IU/ml Relative infectivity
VP62 - 1.7 X 104 1 1.4 X 104 1 1.5 X 104 ± 2.3 X 103 0.209 ± 0.029
+ 3.2 X 103 0.188 3.2 X 103 0.229 3.2 X 103 ± 3.3 X 101
VP62Δgg0 - 8.4 X 103 1 1.2 X 104 1 1.0 X 104 ± 2.3 X 103 0.196 ± 0.058
+ 1.3 X 103 0.155 2.8 X 103 0.237 2.0 X 103 ± 1.1 X 103
VP62Δgg1 - 1.2 X 103 1 3.4 X 103 1 2.3 X 103 ± 1.5 X 103 0.240 ± 0.014
+ 3.0 X 102 0.250 7.7 X 102 0.230 5.4 X 102 ± 3.3 X 102
VP62Δgg2 - 1.8 X 104 1 9.1 X 103 1 1.3 X 104 ± 6.0 X 103 0.234 ± 0.010
+ 4.0 X 103 0.227 2.2 X 103 0.241 3.1 X 103 ± 1.3 X 103
VP62Δgg3 - 1.1 X 104 1 8.2 X 103 1 9.5 X 103 ± 1.8 X 103 0.214 ± 0.068
+ 2.8 X 103 0.262 1.4 X 103 0.165 2.1 X 103 ± 1.0 X 103
VP62Δgg4 - 2.2 X 104 1 1.3 X 104 1 1.7 X 104 ± 6.2 X 103 0.258 ± 0.049
+ 6.4 X 103 0.292 2.9 X 103 0.223 4.7 X 103 ± 2.5 X 103
The 293 T cells were transfected with the XMRV expressing plasmid pVP62 along with the hA3G-V5 or control (pcDNA3) plasmids. The viruses were gathered
2 days post-transfection and were used for infectivity assay with HeLa cells. *The infectious units (IU) were measured from the number of infectious centers that
was normalized by the amount of Capsid in viruses and IU per ml was shown. **The relative infectivity to the HeLa cells infected with the viruses released from the
293 T cells transfected with control plasmid was shown.
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We next investigated the relative infectivities of MXMRV
and XMRV by titration on human HeLa cells, using a
focal immunofluorescence assay [15]. As shown in
Figure 5A, when equal amounts of the two viruses (nor-
malized by CA content) were assayed, the infectivity of
MXMRV was substantially (ca. 36 -fold) higher than that
for XMRV. The difference in infectivity reflected glyco-
gag since the two MXMRV mutants showed infectivities
equivalent to XMRV. Thus M-MuLV glyco-gag can sig-
nificantly enhance the infectivity of XMRV.
We also tested if glyco-gag could be supplied in trans
by transiently co-transfecting 293 T cells with pVP62
and the different glyco-gag expression plasmids, followed
by titration of cell supernatants for infectivity in HeLa
cells as above (Figure 5B). Co-expression of glyco-gag in
XMRV-expressing cells resulted in viruses with enhanced
infectivity.
Cell-specific restriction of XMRV counteracted by
glyco-gag
We also tested the relative infectivities of MXMRV and
XMRV in several human cell lines as well as rat NRK
cells (Table 3). The same viral stocks (normalized for CA
protein) from productively infected 293 T cells were
titrated on the different cell lines (2–4 titrations). It was
interesting that the ratio of MXMRV/XMRV infectivity
ranged from 36 in HeLa cells to 2–4 for 293 and HepG2
cells. In fact the titers of the MXMRV stock measured
on these three cells were similar (e.g. 3.8 X 106 IU/ml for
HeLa vs. 3.9 X 106 IU/ml for 293). However, while
XMRV was somewhat less infectious in 293 cells (1.1 X
106 IU/ml) it was substantially less infectious in HeLacells (1.1 X 105 IU/ml). This indicated a restriction for
XMRV in HeLa cells that could be counteracted by M-
MuLV glyco-gag; the amount or strength of the restric-
tion was less in 293 cells where the infectivity of XMRV
was more similar to MXMRV. DU145 cells also showed
a large MXMRV/XMRV infectivity ratio (20.8), consist-
ent with the presence of glyco-gag sensitive restriction.
However in these cells the infectivity of MXMRV was
lower than for the other human cell lines, suggesting that
these cells also may be less infectable in general. NRK
cells also showed an MXMRV/XMRV infectivity ratio in-
dicative of glyco-gag sensitive restriction (14.5).
Since glyco-gag counteracts the effects of mouse APO-
BEC3 [19], we considered the possibility that the glyco-
gag sensitive restriction in HeLa cells might be due to
one of the 7 human APOBEC3s. hA3G has been shown
to potently suppress XMRV replication [28-31], while
hA3B [30,31] and hA3F [29] have also been reported to
have suppressive activity. The levels of hA3G, hA3B and
hA3F in the different human cell lines were assessed by
RT-PCR (Figure 6). hA3G transcripts were detectable in
293 and 293 T cells, even though they are generally con-
sidered to be functionally hA3G null. HeLa cells were of
greatest interest, since they showed the highest levels of
restriction for XMRV relative to MXMRV; in these cells
only hA3B expression was readily detectable (Figure 6).
Thus if the relative restriction of XMRV in HeLa cells
results from an hA3 proteins, it would likely be hA3B.
DU145 cells, which also showed relative XMRV restric-
tion showed lower but detectable levels of hA3B tran-
scripts. On the other hand, HepG2 cells that show
relatively low levels of XMRV restriction also expressed
hA3B. 293 and 293 T cells did not express appreciable
Figure 3 M-MuLV glyco-gag facilitates XMRV release. A) The organizations of M-MuLV glyco-gag expression plasmids are shown. In some
cases the CTG (CUG) initiation codon for glyco-gag was changed to ATG (AUG) to enhance expression of glyco-gag. B) pVP62 and the glyco-gag
expression vectors were co-transfected into 293 T cells and Gag proteins in the released viruses and the cell lysates were detected by SDS-PAGE
and Western blots with anti-p30CA antibodies. The amount of viral release relative to control viruses is shown. Welch’s t-test with unequal
variances was conducted to detect the difference between mean scores in the two groups and values significantly different from pVP62 alone
(control) are indicated (*, p< 0.01).
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negative for hA3G, they in fact showed detectable tran-
scripts by RT-PCR.)
APOBEC3 proteins are incorporated into HIV-1,
mouse mammary tumor virus and MuLV virions, and
they can inhibit viral replication in recipient cells
[19,28,31-38]. MuLV and HIV-1 infection can also be
restricted by APOBEC3 proteins in recipient cells [32,33],
and glyco-gag can counteract mA3 restriction [19]. In
light of the results of Figure 6, we tested if expression of
hA3B in recipient 293 cells could restrict XMRV infec-
tion. 293 cells stably transfected with an epitope-tagged
hA3B expression plasmid were used for titration of
MXMRV and XMRV, and the resulting titers were com-
pared to titration on 293 cells stably transfected with the
backbone vector (pcDNA3) (Table 4). MXMRV had
higher titers than XMRV on 293/pcDNA3 cells as
expected, and the same was true in 293/hA3B cells. It
was noteworthy that XMRV titers were indistinguishableon the 293/pcDNA3 and 293/hA3B cells. Thus hA3B did
not restrict XMRV infection when expressed in the re-
cipient cells. We also tested if expression of hA3B in vir-
ions affected infectivity of either XMRV or MXMRV.
293 T cells stably infected with these two viruses were
transfected with the hA3B expression plasmid or
pcDNA3, and the resulting viruses were titered on HeLa
cells (Table 5). Expression of hA3B in the virus-
producing cells did not affect the infectivities of either
virus. Thus hA3B did not restrict these viruses when
expressed in the donor infected cell. The lack of hA3B ef-
fect on XMRV infectivity was consistent with a previous
report by Stieler et al.. [28]; in contrast two other groups
have reported that XMRV is restricted by hA3B [29,30].
We confirmed that our hA3B expression vector resulted
in production and packaging of the protein into XMRV
virions (Additional file 3: Figure S3). The antiviral ability
of our hA3B construct was confirmed by using it to in-
corporate hA3B into HIV-1 vector particles encoding
Figure 4 Comparison of XMRV and MXMRV. A) Organization of chimeric expression plasmids is shown. pMXMRV encodes M-MuLV glyco-gag
fused to XMRV Gag protein. To abolish glyco-gag expression from MXMRV virus (MX), the pMXMRV mutants, pMX-3 + 4 and pMX CTG/CA were
generated by substituting nucleotides in or adjacent to the glyco-gag intiation codon (underlined) analogous to glyco-gag negative mutations
generated by other investigators (indicated). B) Viruses harvested from 293 T cells transfected with the different XMRV expression plasmids. In
addition, released viruses were infected into 293 T cells or DU-145 cells and producer cultures were obtained. In this panel the expression of
glyco-gag, poly-Gag and Capsid (CA) proteins in the cell lysates and released viruses from the infected 293 T cells were detected by SDS-PAGE
and Western blotting with anti-p30CA antibody. C) Quantification of the relative % Gag release for pMXMRV compared to pVP62 in the transiently
transfected 293 T cells is shown. D) Quantification of XMRV and MXMRV released from the infected DU145 cells. E) Buoyant density in 20-55%
sucrose gradients of XMRV (diamonds) and MXMRV (squares) released from infected 293 T cells. The densities of each sucrose gradient fraction
were measured, and the amount of viral CA protein in each fraction was quantified by SDS-PAGE and Western blotting. Distribution of the
percent of total CA in each gradient fraction was calculated, and the results are displayed relative to the densities of each fraction. The peak
densities for XMRV and MXMRV are indicated.
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HIV-1 pseudovirus containing hA3B showed approxi-
mately 10-fold reduction of GFP expression in the recipi-
ent 293 T cells (Additional file 4: Figure S4), consistent
with other reports [38,39]. These results indicated that
the glyco-gag dependent restriction for XMRV in human
cells appears to be APOBEC3-independent.
Glyco-gag is maintained in some but not all endogenous
MuLVs
Endogenous retroviruses (ERVs) result from infection by
an exogenous retrovirus into germ cells, and such pro-
viruses can become permanent parts of the genomes of
the progeny of that host. Endogenous retroviruses there-
fore provide insight into the prehistoric viruses at the
time they endogenized into the genome. Included among
the endogenous gammaretroviruses of mice are MuLV
subgroups classified as ecotropic, xenotropic, polytropic
or modified polytropic based on the nature of their enve-
lope proteins (reviewed in [22]). The corresponding
ERVs are referred to as Emv’s, Xmv’s, Pmv’s and Mpmv’srespectively. Laboratory mice represent relatively recent
crosses between European mice (Mus musculus domesti-
cus) and Japanese mice (Mus musculus molossinus) [40].
The endogenous MuLVs from M. domesticus are pre-
dominantly Pmv’s and Mpmv’s, while those from M.
molossinus are predominantly Xmv’s [22,41]. It has re-
cently been shown that XMRV is likely derived by re-
combination between 2 proviruses, and the endogenous
Pmv/Mpmv giving rise to XMRV (preXMRV-2) [26] does
not encode a functional glyco-gag. PreXMRV-2 is
present as a single copy in the genomes of many (e.g.
Harlan nu/nu mice) but not all mouse strains and has
been identified in a few M. m. domesticus mice [26,42].
Thus at the time of endogenization, the then-exogenous
preXMRV-2 likely did not encode glyco-gag.
We investigated if the other endogenous MuLVs of
mice had the capacity to encode a glyco-gag. The gen-
ome has been sequenced for C57BL6 (B6) mice. A bio-
informatic search of the B6 genome identified 48 MuLVs
that were full length or near full length: 1 endogenous
Emv, 10 Xmvs, 23 Pmvs and 13 Mpmvs. The Xmvs were
Figure 5 M-MuLV glyco-gag enhances XMRV infectivity. A) Viruses were gathered from stably infected 293 T cells and measured for infectivity
by the focal immunofluorescence assay (FIA) in HeLa cells. Infectivities were normalized by the amount of Capsid (CA) in each stock and shown
relative to wild-type XMRV. B) pVP62 was co-transfected with different M-MuLV glyco-gag expression vectors into 293 T cells and viruses gathered
from the supernatants were titered in HeLa cells by FIA. Infectivities were normalized for the amount of CA, and the infectivities relative to control
XMRV (co-transfection with empty expression vector) are shown. Welch’s t-test with unequal variances was conducted to detect the difference
between mean scores in the two groups and values significantly different from XMRV (A) or pXMRV control (B) are indicated (*, p< 0.05. **,
p< 0.01).
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C) [43]. Phylogenies based on the nucleotide similarities
in the glyco-gag regions (nt 1–264, for M-MuLV J02255
nt 357–620) are shown for representative proviruses in
Figure 7, and predicted peptides beginning with the pu-
tative CUG initiation codon for glyco-gag are shown in
Figure 8. Included in this analysis are specific exogenous
MuLVs (e.g. AKV, DG75, and Moloney MuLVs). Xmv
clade A proviruses grouped with Pmv and Mpmv pro-
viruses, and also with XMRV/PreXMRV-2 (Figure 7). All
of the endogenous viruses in this group could not en-
code a glyco-gag (Figure 8). Thus the primordial MuLVs
in this group presumably could replicate in mice without
glyco-gag, although none of these ERVs are known to
produce infectious MuLVs.
In contrast, clade B and C endogenous xenotropic pro-
viruses could theoretically encode classical glyco-gags, i.e. they contained a contiguous upstream coding sequence
in the same reading frame as Pr65gag, beginning with a
CUG codon. Moreover, the predicted amino acid
sequences showed substantial amino acid identity with
the consensus sequence for the current exogenous
MuLVs (Figure 8). It is also interesting that Clade C
glyco-gag is identical over the first 70 amino acids with
the glyco-gag of two endogenous ecotropic MuLVs (AKV
of AKR mice and Emv2 of C57BL mice). Both AKV and
Emv2 can spontaneously activate and establish infections
(and leukemias) in mice [44], although Emv2 produces
virus at much lower efficiency due to a single replace-
ment mutation in pol [45]. The exogenous SL3-3 MuLV
derived from AKV MuLV has an identical glyco-gag to
that of AKV MuLV. Likewise the Clade B xenotropic pro-
viruses Xmv-8/10 have a glyco-gag that is highly related
(97.7% amino acid identity) to a replication-competent
Table 3 Comparing cell lines to infection with XMRV and MX viruses
Recipient cells Virus Trial 1 Trial 2 Trial 3 Trial 4 Ave ± Std Ave
IU/ml* IU/ml IU/ml IU/ml IU/ml Relative infectivity** MX/XMRV
HeLa XMRV 1.0 X 105 8.8 X 104 1.6 X 105 8.0 X 104 1.1 ± 0.38 X 105 1 ± 0 36.0
MX 4.3 X 106 3.1 X 106 4.5 X 106 3.1 X 106 3.8 ± 0.78 X 106 36.0 ± 6.52
293 XMRV 5.9 X 105 1.2 X 106 1.4 X 106 1.1 ± 0.42 X 106 9.24 ± 3.64 3.89
MX 3.5 X 106 4.2 X 106 4.2 X 106 3.9 ± 0.38 X 106 35.9 ± 11.1
HepG2 XMRV 8.7 X 105 2.0 X 106 9.6 X 105 1.3 ± 0.63 X 106 11.4 ± 1.28 2.95
MX 2.0 X 106 7.7 X 106 2.5 X 106 4.1 ± 3.2 X 106 33.6 ± 12.4
NRK XMRV 1.2 X 105 2.9 X 104 7.4 ± 6.3 X 104 0.754 ± 0.593 14.5
MX 1.2 X 106 8.4 X 105 1.0 ± 0.29 X 106 10.9 ± 2.01
DU145 XMRV 8.4 X 103 5.1 X 103 6.7 ± 2.3 X 103 0.0705 ± 0.0176 20.8
MX 1.5 X 105 1.2 X 105 1.4 ± 0.21 X 105 1.47 ± 0.0846
The several cell lines were infected with XMRV or MX viruses that were produced from the infected 293 T cells (293 T/XMRV and 293 T/MX). *The infectious units
(IU) were measured from the number of infectious centers that was normalized by the amount of Capsid in viruses and IU per ml was shown. **The relative
infectivity to HeLa cells infected with XMRV viruses was shown.
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http://www.retrovirology.com/content/9/1/58xenotropic MuLV originally found in released from
human DG-75 leukemia cells [46]. In summary, two of
the three clades of endogenous xenotropic MuLV pro-
viruses can encode a glyco-gag, while one (Clade A) can-
not. The endogenous Pmv and Mpmv proviruses cannot
encode glyco-gag.
Discussion
In this report, we used XMRV to investigate MuLV
glyco-gag. XMRV is a recombinant between two en-
dogenous proviruses in the mouse genome, preXMRV-1
and preXMRV-2, and it provides insight into the pro-
genitor viruses that endogenized the mouse genome dur-
ing evolution. The 5’ end of the XMRV genome, which isFigure 6 RNA expression of APOBEC3s in different cell lines.
The cellular RNAs isolated from several human cell lines were
subjected to RT-PCR with primers for human APOBEC 3 G (hA3G),
hA3B, hA3F and GAPDH. The amplified PCR products were separated
by agarose gels and visualized by ethidium bromide staining. (RT-),
omission of reverse transcriptase from the reactions. NC, control with
no added RNA.where glyco-gag is encoded, is derived from preXMRV-2.
While XMRV does not encode a classical glyco-gag,
there are two open reading frames in the 5’ end of the
genome that could potentially encode glyco-gag activity.
However, mutation of either of these potential reading
frames had no measurable effect on viral release or in-
fectivity, indicating that XMRV does not encode glyco-
gag function. On the other hand, XMRV can respond to
glyco-gag (albeit less than M-MuLV), since a chimeric
XMRV encoding in-frame glyco-gag from M-MuLV
(MXMRV) showed enhanced virus release through lipid
rafts and enhanced infectivity. Expression of M-MuLV
glyco-gag in trans could also enhance viral release and in-
fectivity. Studies on the infectivities of MXMRV vs
XMRV showed different effects in different human cell
lines, which revealed relative restriction of XMRV in
some human cells (e.g. HeLa) compared to others (e.g.
293); the restriction could be overcome by M-MuLV
glyco-gag.
As shown in Figure 2, mutations designed to interfere
with translation of two upstream ORFs in XMRV did not
significantly affect infectivity or virus release, which
allowed us to conclude that the putative 53 or 58 amino
acid proteins were not important for viral replication.
For one of these mutants, VP62Δgg1, there was approxi-
mately 80% reduction in infectivity. However, there was
also an equivalent reduction in incorporation of viral
RNA into released virus, which suggested that the
reduced RNA incorporation was the cause of the
reduced infectivity. For M-MuLV, there are several stem-
loop structures in the region encoding glyco-gag (includ-
ing the CUG initiation codon in one loop), and this re-
gion of the genome contains the RNA packaging (Psi)
sequences [47]. It is thus likely that the analogous region
of XMRV is important for RNA incorporation. Use of
the M-fold program [48,49] on nucleotides 1–607 of
Table 4 Expression of hA3B in 293 cells did not alter infectivity of XMRV or MX viruses
Virus Recipient cells Trial 1 Trial 2 Trial 3 Trial 4 Ave± Std
IU/ml* IU/ml IU/ml IU/ml IU/ml Relative infectivity**
XMRV 293/pcDNA3 2.5 X 106 2.9 X 106 1.7 X 106 2.9 X 106 2.5 ± 0.52 X 106 1 ± 0
293/hA3B 2.2 X 106 2.3 X 106 2.5 X 106 4.3 X 106 2.8 ± 0.97 X 106 1.17 ± 0.365
MX 293/pcDNA3 6.5 X 106 6.9 X 106 5.1 X 106 8.3 X 106 6.7 ± 1.3 X 106 2.73 ± 0.231
293/hA3B 6.9 X 106 9.0 X 106 3.6 X 106 8.2 X 106 6.9 ± 2.4 X 106 2.72 ± 0.462
The 293 cells transfected with the plasmid encoding HA-tagged hA3B plasmids (293/hA3B) or control plasmids (293/pcDNA3) were selected by G418 and were
used as recipient cells for infectivity assay. The recipient cells were infected with XMRV or MX viruses that were produced from the infected 293 T cells. *The
infectious units (IU) were measured from the number of infectious centers that was normalized by the amount of Capsid in viruses and IU per ml was shown.
**The relative infectivity to the 293/pcDNA3 infected with XMRV viruses was shown.
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http://www.retrovirology.com/content/9/1/58XMRV predicted several stable stem-loops, and the nu-
cleotide (382) mutated in VP62Δgg1 would normally be in
a stem; the predicted structure of the mutant RNA showed
an additional loop in this stem (T. Nitta and H. Fan,
unpublished). The secondary structure of 5’ end of the
XMRV genome predicted by SHAPE (selective 2’-hydroxyl
acylation analyzed by primer extension) also suggested
that the region corresponding to the mutation in
VP62Δgg1 may form a stem structure, and that it may be
involved in the formation of intermolecular loop-loop kis-
sing interactions in RNA dimers [50]. This supports the
idea that the region encompassing the VP62Δgg1 muta-
tion is important in packaging of viral RNA into virions.
Reports from us and others have suggested there are
multiple functions for glyco-gag, although the regions of
glyco-gag responsible for the different activities remain
to be fully elucidated [15-19]. In our studies describing
enhancement of virus release through lipid rafts for
MuLV and HIV-1, the unique N-terminal 88 amino acids
(expressed by pHA-gg88) were sufficient for this activity
[17]. Likewise, in this study, pHA-gg88 was sufficient to
maximally enhance XMRV release from cells (Figure 3).
On the other hand, additional glyco-gag sequences are
required to enhance infectivity of nef-negative HIV-1 and
glyco-gag negative MuLV from lymphocytes: the N-
terminal 189 amino acids are required for full enhance-
ment, and a 96 amino acid N-terminal fragment showed
60% activity [18]. Consistent with this, we found thatTable 5 Expression of hA3B in 293 T cells infected with XMRV
Donor cells Trial 1 Trial 2 Trial 3
ICs/ml* ICs/ml ICs/ml
293T/XMRV/pcDNA3 7.0 X 104 l.3 X l05 l.5 X 105
293T/XMRV/hA3B 8.5 X 104 l.0 X l05 l.4 X l05
293T/MX/pcDNA3 8.4 X 105 1.4 X 106 3.2 X 106
293T/MX/hA3B 1.0 X 106 l.9 X 106 4.1 X 106
The infected 293 T cells were transfected with the plasmid encoding HA-tagged hA
(293 T/XMRV/pcDNA3 and 293 T/MX/pcDNA3). HeLa cells were infected with XMRV
(IU) were measured from the number of infectious centers that was normalized by t
infectivity to the HeLa cells infected with the virus released from 293 T/XMRV/pcDNHA-gg88 enhanced XMRV infectivity 40-60% as well as
full-length gPr80gag (Figure 5).
Studies on the infectivities of MXMRV vs XMRV in
different human cells indicated that some cell lines
(e.g. HeLa) showed substantially higher susceptibility/
infectibility for MXMRV than for XMRV (≥ 20-fold,
Table 3), while for other cell lines, the two viruses had
more similar titers (≤ 5-fold difference); this reflected
more efficient replication of XMRV in the latter cells.
Glyco-gag in virions might affect viral factors (e.g. effi-
cient incorporation of Env into virions or change of viral
core nature), which would provide a missing activity (e.g.
viral attachment or entry) required to infect certain cell
lines. The results of infectivities would also be consistent
with restrictive cells (e.g. HeLa) expressing a factor that
restricts XMRV replication, but which can be overcome
by glyco-gag. Cells such as 293 would not express or ex-
press lower amounts of the factor. Comparisons between
cell lines that differ in relative restriction of HIV-1 have
led to the discovery of cellular restriction factors for HIV-
1 replication (such as APOBEC3G and Trim5alpha
[51,52]), and our results might lead to identification of a
novel restriction factor for XMRV in human cells. The
experiments of Figure 6 and Tables 4 and 5 further indi-
cated that the cell specific variation in restriction of
XMRV observed here is not due to hA3 proteins, even
though hA3G, and potentially hA3B and hA3F can re-
strict XMRV in vitro./MX did not affect viral infectivity
Trial 4 Ave± Std
ICs/ml ICs/ml Relative infectivity**
1.5 X 105 l.2 ± 0.37 X l05 1 ± 0
l.2 X l05 1.1 ± 0.23 X l05 0.931 ± 0.185
3.3 X 106 2.2 ± 1.2 X 106 16.7 ± 5.91
3.3 X 106 2.6 ± 1.4 X 106 19.8 ± 6.22
3B plasmids (293 T/XMRV/hA3B and 239 T/MX/hA3B) or control plasmids
released from the viral producing cells described above. *The infectious units
he amount of Capsid in viruses and IU per ml was shown. **The relative
A cells was shown.
Figure 7 Phylogenetic analysis of glyco-gag nucleotide sequences in MuLVs. The nucleotide sequences in the glyco-gag region for
endogenous MuLVs (nt 1–264, for M-MuLV J02255 nt 357 – 620) were aligned by DNASTAR Lasergene 8 MegAlign (Clustal W method) and a
phylogenetic tree is shown. The same regions from representative exogenous MuLVs of the Friend-Moloney-Rauscher (FMR) group are also
aligned. Box with the dark shading indicates endogenous MuLVs that do not have sequences capable of encoding glyco-gag. Boxes without
shading contain viruses or endogenous MuLVs that can encode glyco-gag.
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http://www.retrovirology.com/content/9/1/58The exogenous MuLV that endogenized to form
preXMRV-2 presumably could replicate in mice at the
time of endogenization. Indeed the preXMRV-2 provirus
contains full gag, pol and env genes, although it cannot
encode functional glyco-gag. It was therefore of interest
to investigate whether other endogenous proviruses in
the mouse genome could encode glyco-gag or not. En-
dogenous MuLV proviruses have been grouped into eco-
tropic, xenotropic, and polytropic subgroups based onFigure 8 Comparison of MuLV glyco-gag amino acid sequences. Amin
virus (M-MuLV) and Xeno Clade B and C endogenous MuLVs at the top of
contiguous with the frame for Gag polyprotein. For Xeno Clade B and C, al
homology in the glyco-gag region (DG-75 MuLV and AKV-MuLV/Emv-2 resp
lower part of the figure (shaded box), predicted amino acids from endogen
predicted open reading frames close before the beginning of the coding s
between these MuLVs and the glyco-gag positive MuLVs and MuLVs. The g
Lasergene 8 MegAlign (Clustal W method).sequence homologies and whether their predicted Env
proteins can mediate infection of murine and non-
murine cells [22] (Additional file 5: Table S1). The poly-
tropic ERVs have been subdivided into Pmvs and Mpmvs
[53], and xenotropic ERVs (Xmvs) have been further sub-
divided into three clades (A, B and C) based on nucleo-
tide sequence comparisons [43]. As shown and described
in Figure 7, based on the 5’ (glyco-gag) regions, XMRV
and preXMRV-2 grouped with clade A Xmvs and alsoo acid sequence alignments are shown for a representative FMR group
the figure. For all of these cases, the glyco-gag reading frame is
ignments are also shown for replication-competent viruses with high
ectively). *, amino acids shared among all of the glyco-gags. In the
ous MuLVs that cannot encode full-length glyco-gag are shown. The
equences for Gag polyprotein. *, predicted amino acids shared
lyco-gag amino acid sequences in MuLVs were aligned by DNASTAR
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http://www.retrovirology.com/content/9/1/58the Pmvs and Mpmvs. None of these viruses could en-
code glyco-gag, indicating that the exogenous progeni-
tors for all of these viruses could replicate in mice in the
absence of glyco-gag. On the other hand, clade B and C
Xmvs would be predicted to encode glyco-gags (Figure 7).
It was interesting that replication-competent MuLVs
with glyco-gags highly similar or identical to those of
clade B and C xenotropic proviruses have been isolated
– i.e. the leukemogenic SL3-3 MuLV (derived from the
endogenous ecotropic MuLV AKV) for clade C and the
xenotropic MuLV DG-75 for clade B [46]. Thus the ex-
ogenous progenitors for the clade B and C xenotropic
proviruses encoded glyco-gag at the time of
endogenization.
The results of Figure 7 raise the question as to when
glyco-gag developed during evolution of the murine
gammaretroviruses. At first glance the shape of the
phylogenetic tree in Figure 7 might suggest that glyco-
gag was present in more ancient gammaretroviruses, and
that it was subsequently lost in the progenitors for clade
A Xmvs, Pmvs, and Mpmvs. Laboratory mice are hybrids
between European mice (rich in Pmv and Mpmv pro-
viruses) and Asian mice (rich in Xmvs) [40,54], and the
cluster of ERVs lacking glyco-gag largely derived from
the western European M. m. domesticus. Arguments exist
for whether glyco-gag negative MuLVs preceded glyco-
gag positive viruses, or vice versa. A glyco-gag – like pro-
tein (upstream ORF in-frame with the equivalent of
Pr65gag ) is encoded by gammaretroviruses of several
other mammalian species (feline leukemia virus [2],
Gibbon ape leukemia virus [M. Pizzato, personal com-
munication] and koala retrovirus [55]). Moreover the
putative glyco-gag coding sequence of FeLV is also
present in two endogenous FeLV-related proviruses in
the cat genome (T. Nitta and H. Fan, unpublished), so
glyco-gag was present in the primordial FeLV genome
at the time it endogenized in cats. This conservation
would support development of glyco-gag before radi-
ation of gammaretroviruses to these different species,
although we have not tested if these putative glyco-gags
have equivalent function.
On the other hand, if glyco-gag negative MuLVs devel-
oped from glyco-gag positive viruses, what would be the
driving force for loss of glyco-gag? One possibility could
be that mice developed a restriction factor against glyco-
gag, so that loss of glyco-gag could have facilitated
MuLV replication in these mice. Nevertheless, exogenous
MuLVs (glyco-gag positive) replicate efficiently in labora-
tory mice suggesting they carry no such factor, and in-
activation of glyco-gag reduces infectivity in vivo [19]. It
was interesting that the 5’ region of the glyco-gag nega-
tive proviruses (and XMRV) have CUG codons and im-
mediately downstream sequences that would encode
amino terminal highly conserved glyco-gag amino acids(Figure 8). This would be more consistent with loss of
glyco-gag from initially glyco-gag positive viruses.
Conclusion
A functional glyco-gag is not encoded by XMRV. M-
MuLV glyco-gag can compensate for this defect and
enhance XMRV replication. The ability of glyco-gag to
increase XMRV infectivity varies in different human cell
lines, implying that there is a factor restricting XMRV
replication in human cells and it can be overcome by
glyco-gag. The ability of M-MuLV glyco-gag for enhan-
cing XMRV replication is independent of hAPOBEC3.
Comparative analysis with leader sequences in endogen-
ous gammaretroviruses of mice indicated that the viruses
that gave rise to some but not all clades of xenotropic
Xmvs had the potential to encode glyco-gag.
Methods
Cells
Human cell lines 293 (kidney), 293T (kidney), HepG2
(hepatocyte carcinoma), DU145 (prostate carcinoma)
and HeLa (cervical cancer) cells and rat NRK (kidney)
cells were grown in Dulbecco’s modified Eagle’s medium
supplemented with penicillin (100 U/ml), streptomycin
(100 mg/ml) and 10% fetal bovine serum. For examining
the relation between hA3B and glyco-gag, 293 cells were
transfected with HA-hA3B and were selected by G-418
(Gold Biotechnology). The selected 293 cells were grown
in Dulbecco’s modified Eagle’s medium supplemented
with penicillin, streptomycin, 10% fetal bovine serum
and 400 ug/ml of G-418.
DNA constructs
The full-length XMRV molecular clone pVP62 was
described previously [20]. The XMRV mutants contain-
ing stop codons in or adjacent to the putative glyco-gag,
gg53 and gg58 were made by site-directed mutagenesis
(Figure 1 and Table 1) according to standard techniques.
Details will be provided upon request. pMXMRV was
constructed as follows. First, the M-MuLV R, U5 and
leader sequence region was PCR amplified from the M-
MuLV plasmid p63-2 [56] using the primers 5’ -
aaaaagcggccgcgcgccagtcctccgattgactg and 5’ – aaaaactc-
gagattctcagacaaatacagaaacac, and then cloned into pCR4-
TOPO. The M-MuLV sequences from this plasmid were
excised by digestion with XhoI and BsiWI and ligated
into a subclone of the XMRV gag sequence (from
pVP62) similarly digested with XhoI and BsiWI, to give
pMX-TOPO. This placed the M-MuLV glyco-gag coding
sequence in frame with the first amino acid of XMRV
gag. The M-MuLV R, U5 and leader sequence regions as
well as a portion of XMRV gag was isolated from pMX-
TOPO by digestion with NotI and BsiWI, and cloned in
place of the XMRV R, U5, leader peptide and gag
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give pMXMRV. To abolish glyco-gag expression from
MXMRV, the pMXMRV mutants, pMX-3 + 4 and pMX
CTG/CA (Figure 4) were generated by site-directed mu-
tagenesis. p8065-2 is an expression plasmid for M-MuLV
glyco-gag, and has been described previously [15]. The
M-MuLV gPr80gag expression vectors, p8065-2-HBH and
pEGFP-8065-2 S were generated from
p8065-2 by standard cloning techniques. p8065-2-HBH
expresses full-length chimeric glyco-gag, with the HBH-
tag (two 6-his tags flanking a biotinylation site [57])
inserted in the BsrGI site in p15MA region (M-MuLV se-
quence J02255 nt 921) of M-MuLV Gag. p8065-2S-GFP
encodes enhanced jellyfish green fluorescent protein
(EGFP) used to the N-terminus of glyco-gag; in this con-
struct the AUG for Gag polyprotein (Pr65gag) was
mutated (AUG!AUC) to reduce translation of Pr65gag
from this construct. pHA-gg88, which encodes only the
N-terminal 88 amino acids of M-MuLV glyco-gag (with
an N-terminal HA epitope) was described previously
[17]. The APOBEC expression vectors, pcDNA3.1D.
APOBEC3G.V5 (hA3G-V5) were described previously
[58]. The plasmid encoding hA3B was obtained from
OpenBiosystem. The hA3B sequence was amplified by
the primers, 5’ - aaaaactcgagctcgag gccaccaatccacagatca-
gaaatccg and 5’ - aaaaagcggccgctcacgtgtgtgttctcctgaag.
The amplified PCR product was digested with XhoI and
NotI and ligated into an expression plasmid for HA-
tetherin [59] digested with the same enzymes.
Antibodies and Chemicals
Rabbit polyclonal anti-MuLV p30CA antiserum was
described previously [60]. For detection of hA3G-V5,
mouse anti-V5 antibody was used (Invitrogen). We used
anti-mouse IgG conjugated with horseradish peroxidase
(Thermo Scientific) and anti-rabbit IgG conjugated with
horseradish peroxidase (GE Healthcare) for Western
blots. In the focal immunofluorescence assay, the goat
anti-rabbit IgG conjugated with Alexa Fluor 488 (Invitro-
gen) was used to visualize foci of the infected cells. The
Calphos Mammalian Transfection Kit (Clontech) and
BioT (Bioland Scientific LLC) were used for
transfections.
Infectivity assay
Titrations of viruses (XMRV, MXMRV and their deriva-
tives) were performed by a focal immunofluorescence
assay described previously [15] with slight modification.
Briefly, 2 x 105 target cells were seeded per 6-cm plate
18–24 h prior to infection. Dilutions of the viral stocks
were then adsorbed to the cells in the presence of 8 μg/
ml polybrene (1,5-dimethyl-1,5-diazaundecamethylene
polymethobromide, Sigma) for 16 hr, followed by the
addition of growth medium. At 5 days post-infection, thecells were fixed by 4% paraformaldehyde and then were
incubated with the blocking buffer containing 10% calf
serum and 1% Triton X-100 in PBS. The cells were trea-
ted with anti-MuLV p30CA for 2 h at 4 °C, washed with
phosphate-buffered saline (PBS) supplemented with 1%
bovine serum albumin, and then stained for 1 h at 4 °C
with a secondary fluoresence-conjugated anti-rabbit IgG
antibody. The plates were washed three times, and foci
of immunofluorescence were counted with a UV micro-
scope. The amount of Gag in virions was determined by
Western blots and immuno-densitometry, and used for
normalization of infectivity.Detection of viruses by western blots
Detection of viral antigens by Western blots and assess-
ment of virus release was described previously [16]. In
brief, the cells transfected with XMRV expressing plasi-
mids or the infected cells were seeded on 6-cm dishes
one day before measuring viral release. The media were
replaced once and cells were incubated for 6 hours; and
then both cells and viruses were gathered. The media
were clarified by low-speed centrifugation, were passed
through a 0.45 μm filter and viral particles, and were pel-
leted in a Beckman SW41 rotor at 77,000 g for 1 hour.
The pelleted viral particles and corresponding cell lysates
were analysed by SDS-PAGE and Western blots using
anti-MuLV p30CA. To quantify viral release, each poly-
Gag and CA bands in the cells and media was quantified
with the densitometry software AlphaEaseFC (Alpha
Innotech), and the percentage of released Gag divided by
total Gag proteins (poly-Gag and CA) in cells and media
was calculated. Different exposures of the blots were
analyzed to ensure that densitometry was in the linear
range.Detection of viral RNA in virions
The viruses were gathered from the 293 T cells transfected
with the XMRV plasmids, pVP62 or pVP62Δgg0-4. The
released viruses into media were harvested by centrifuga-
tion as described above. The RNA in the viral pellets was
isolated by NucleoSpin RNAII (Macherey-Nagel) and trea-
ted with DNase (Deoxyribonuclease I, Amplification
Grade, Invitrogen). Then, RNA was used for cDNA syn-
thesis (qScript cDNA Synthesis Kit, Quanta Biosciences).
The cDNA samples were subjected to real-time PCR with
SYBR Green PCR Master Mix (Applied Biosystems) and
primers for XMRV (forward primer 5’ – gtggcctacctgtc-
caaaaa and reverse primer 5’ – gggttgtttgaccagtgctt). The
amount of CA in virions was determined by Western blots
and immuno-densitometry and was used for
normalization. The results are expressed at relative viral
RNA levels compared to those released from the 293 T
cells transfected with wild-type XMRV.
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Total RNA was isolated from cell lines with the RNA
isolation kit, NucleoSpin RNAII. One μg of the RNA was
treated with Deoxyribonuclease I, Amplification Grade
(Invitrogen), and was used for synthesizing cDNA
(qScript cDNA Synthesis Kit, Quanta Biosciences). The
cDNA samples were subjected to PCR with the primers
described previously [28]. GAPDH was also amplified as
internal control.
Glyco-gag sequences of endogenous MuLVs
Proviral sequences for the ecotropic, xenotropic and
polytropic MuLVs were extracted from the sequenced
C57BL genome using previously published information
on their chromosomal locations, env subtype and coding
potential [43,61] (Additional file 5: Table S1).
Statistical analysis
A Student’s or Welch’s t-test with equal or unequal var-
iances, respectively, was conducted to detect the differ-
ence between mean scores in the two groups, based on
the equality test of two variances.
Additional files
Additional file 1: Figure S1. Enhancement of XMRV release by
M-MuLV glyco-gag. pVP62 (XMRV expression plasmid) and different
M-MuLV glyco-gag expression vectors were co-transfected into 293T cells
and 48 hr later Gag proteins in the cell lysates and the released viruses
were detected by SDS-PAGE and Western blot with anti-p30CA antibodies.
Additional file 2: Figure S2. Virus release by XMRV and MXMRV.
293T cells were transiently transfected with pVP62 (XMRV expression
plasmid) or pMXMRV (MX), and Gag proteins in the cell lysates and the
released viruses were detected. Equivalent analysis was performed on
DU145 cells productively infected with XMRV and MXMRV.
Additional file 3: Figure S3. Incorporation of hA3B into XMRV and
MXMRV. A) To assess the expression ability of the epitope-tagged hA3B
expression plasmid, 293 cells were transfected with HA-hA3B and
selected by G-418. hA3B protein in cell extracts from the selected 293
cells was detected by anti-HA antibodies. B) To generate XMRV and
MXMRV (MX) viruses containing hA3B, 293T cells were transiently
transfected with pVP62 or pMXMRV along with HA-hA3B or pcDNA3
(control). Gag and hA3B proteins in the cell lysates and the virions
released from the transfected 293T cells were detected by SDS-PAGE and
Western blotting for anti-p30CA and anti-HA antibodies. hA3B was
incorporated into XMRV and MXMRV virions with equivalent efficiency.
Additional file 4: Figure S4. Inhibition of HIV infection by hA3B.
293T cells were transiently co-transfected with the expression vectors,
pCMV-dR8.74 (HIV-1 Gag-Pol), pMD2.G (VSV-G), pLVTHM (HIV-1-based
vector expressing EGFP, http://www.addgene.org/12247) along with
HA-hA3B or pcDNA3 (control). A) HIV-1 Gag proteins and hA3B in the
transfected 293T cells and viruses were detected by SDS-PAGE and
Western blot with anti-p24 and anti-HA antibodies. The pseudoviruses
with hA3B released from the transfected 293T cells were used for titering
HIV-1 infectivity. B) The vector stocks produced in the panel A were used
to infect fresh 293T cells, and the GFP-positive cells were counted 2 days
post-infection. The relative numbers of GFP-positive cells, normalized for
p24 in the vector stocks, are shown. The value for the control vector
lacking hA3B (pcDNA3) was set at 1. C) As a second measure of
infectivity, equal volumes of vector stocks shown in the panel A were
used for infection of fresh 293T cells. At 3 days post-infection, the amount
of EGFP protein in the infected cells was determined by SDS-PAGE andWestern blotting with anti-EGFP antibodies. The Western blot data and
the relative volumes of each sample loaded on the gel are shown. When
corrected for the amount of vector (as assessed by p24 protein), the
inhibition of HIV vector infection by HA-hA3B was consistent with the
infectivity assay in the panel B.
Additional file 5: Table S1. Endogenous ecotropic, xenotropic,
polytropic and modified polytropic MuLVs in the sequenced C57BL
genome. GenBank accession numbers are provided for the BAC clones
containing the ERVs along with the positions of the viral sequences and
the presence or absence of the consensus glyco-gag sequence is noted.
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